Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on West Pharmaceutical Services (WST) and increased the price target from $440 to $470.
February 13, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keybanc analyst Paul Knight has reaffirmed an Overweight rating on West Pharmaceutical Services and raised the price target from $440 to $470.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100